|
|
|
| home > pmps > spring 2004 > assessing the implications of the new drug labelling legislation |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The issues surrounding the labelling of pharmaceutical products have generated considerable coverage in the press over the last few months. This upsurge in interest has been sparked by two imminent changes in labelling legislation. The first comes from the FDA and relates to licensed products, while the second change is driven by the European Union and focuses on investigational products. This article will consider the implications these changes will have on the assembly and packaging of pharmaceutical products.
FDA Final Ruling
On 25th February this year, the FDA issued its final ruling on the requirement to include bar codes on the packaging of human drug products and biological products. The motive behind the ruling is the desire to reduce the number of adverse events and transfusion errors that occur - the FDA estimates that this new ruling will prevent over 500,000 such errors over a period of 20 years, with an associated cost saving of billion in the same period.
In some hospitals that are already using bar coding systems, medication error rates have been reduced by as much as 85 per cent and one hospital in the US has administered 5.7 million doses of medication to date without a single error. On the downside, according to the FDA's own figures, the financial impact of this ruling on the pharmaceutical industry is expected to be million in the first two years. Despite this, there has been widespread support for this approach to improving patient safety from health care professionals, hospitals and trade and professional associations alike. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EMBALLAGE 2012
19-22 November 2012, Paris Nord Villepinte, France
EMBALLAGE has clearly delineated sectors to make the decision-maker’s task easier when visiting and to highlight all the industry’s know-how: machinery and packaging for the food and cosmetics sectors, health solutions and luxury packaging and containers, etc. Hence, EMBALLAGE provides a bespoke solution for each industry
More info >> |
|
 |
News and Press Releases |
 |
Norwich Expands Capabilities for Phase I-III Clinical Trials
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >> |
|
|
